Bromocriptine Mesylate
Overview
Bromocriptine Mesylate is an ergot derivative medication primarily used in the treatment of hyperprolactinemia, Parkinson's disease, and Type 2 diabetes. It acts as a dopamine D2 receptor agonist to inhibit the secretion of prolactin from the pituitary gland.
API suppliers (6)
Suppliers of Bromocriptine Mesylate evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 2 of 6 suppliers.
1 of 6 holds a GMP certificate on record in the EU or UK registers
- CURIA ITALY SRLItaly1 active DMF GMP on record
- TAPI NL BVNetherlands1 active DMF
- CHEMAPOL LTD
- LABOCHIM
- CHEMICAL PHARMACEUTICAL RESEARCH INSTITUTE NIHFI LTD
- GALENA AS
Therapeutic areas
Do you supply Bromocriptine Mesylate? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.